Company intelligence / Profile preview
Polaryx Therapeutics
Paramus, New Jersey, United Statespolaryx.com ↗
- Ownership
- Public · PLYX
- Development stage
- Phase 3
01
Overview
Polaryx’s lead candidate, PLX‑200, has advanced to Phase 3 clinical trials for Juvenile Neuronal Ceroid Lipofuscinosis. Preclinical studies of their pipeline have shown improved motor/cognitive function and increased life expectancy in animal models of lysosomal storage disorders. The company has received FDA Orphan Drug and Rare Pediatric Disease designations for its programs targeting Niemann-Pick Diseases A/B with PLX‑300.
- Therapeutic areas
- Rare DiseasesNeurology
- Modalities
- Small molecules (oral)Gene therapy (intranasal)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Collaboration with Rush University Medical Center for preclinical research validationSeeking additional partners
04
Financials
- Market cap
- $86.7M
- Total revenue
- $0
- Enterprise value
- $75.2M
Beyond the preview
Go deeper on Polaryx Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Polaryx Therapeutics.